BioCentury | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

...China’s NMPA approves Cimzia to treat RA China’s National Medical Products Administration (NMPA) approved Cimzia certolizumab pegol...
...Review. UCB will collaborate with Cinkate Pharmaceutical Corp. (Chicago, Ill.) to promote patient access to Cimzia...
...2A; TNFα - Tumor necrosis factor α; 5-HT2A (HT2RA) - serotonin receptor 2A BioCentury Staff Cimzia, certolizumab pegol (CDP 870) lumateperone...
BioCentury | Apr 26, 2019
Clinical News

Lilly planning submissions for Taltz in non-radiographic axial spondyloarthritis

...for systemic therapy or phototherapy, and for active psoriatic arthritis. Last month, FDA approved Cimzia certolizumab pegol...
...from UCB S.A. (Euronext:UCB), is the first and only FDA-approved treatment for the indication (see “Cimzia...
...Targets: IL-17A - Interleukin-17A; TNFα - Tumor necrosis factor α Brian Moy, Assistant Editor Cimzia, certolizumab pegol (CDP 870) Taltz...
BioCentury | Apr 5, 2019
Company News

Cimzia approved for non-radiographic axial spondyloarthritis

...FDA approved Cimzia certolizumab pegol to treat non-radiographic axial spondyloarthritis. FDA said the drug, from UCB S.A...
...FDA said the drug, from UCB S.A. (Euronext:UCB), is the first approved for the indication. Cimzia...
...deal that have given Dermira rights to develop and commercialize Cimzia for psoriasis. Meghan Sullivan, Assistant Editor Cimzia Dermira...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...cinacalcet (Mimpara) $1,718.0 $1,326.0 $1,768.0 3% UCB S.A. (Euronext:UCB) / Astellas Pharma Inc. (Tokyo:4503) Cimzia certolizumab pegol...
BioCentury | Aug 3, 2018
Clinical News

UCB's Cimzia meets in Phase III for non-radiographic axial spondyloarthritis

...UCB S.A. (Euronext:UCB) reported in May that Cimzia certolizumab pegol met the primary endpoint in the Phase...
...the EU. Dermira Inc. (NASDAQ:DERM), Menlo Park, Calif. UCB S.A. (Euronext:UCB), Brussels, Belgium Product: Cimzia certolizumab pegol...
...40 (ASAS40) response at week 12 Status: Phase III data Milestone: NA Jaime De Leon Cimzia, certolizumab pegol (CDP 870) Dermira...
BioCentury | Jul 12, 2018
Politics & Policy

ICER panel votes against elagolix for endometriosis

...two voted the value was low and one voted that it was high. For Cimzia certolizumab pegol...
...mAb targeting the p19 subunit of IL-23, for moderate to severe plaque psoriasis in adults. Cimzia...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...cinacalcet (Mimpara) $1,582.0 $1,305.0 $1,740.0 10% UCB S.A. (Euronext:UCB) / Astellas Pharma Inc. (Tokyo:4503) Cimzia certolizumab pegol...
BioCentury | Jul 7, 2017
Finance

Onward and upward

...UCB S.A. (Euronext:UCB) / Dermira Inc. (NASDAQ:DERM) FDA issues a complete response letter for Cimzia certolizumab pegol...
BioCentury | Apr 28, 2017
Clinical News

Cimzia regulatory update

...UCB said FDA issued a complete response letter in March to an sBLA for Cimzia certolizumab pegol...
...it is working with FDA and a third party bioanalytical laboratory to address the issue. Cimzia...
...Inc. (NASDAQ:DERM), Menlo Park, Calif. UCB S.A. (Euronext:UCB), Brussels, Belgium Product: Cimzia certolizumab pegol Business: Autoimmune Julian Zhu certolizumab pegol Cimzia Dermira...
BioCentury | Apr 24, 2017
Company News

UCB reveals CRL for Cimzia

...its 1Q17 earnings report that FDA issued a complete response letter last month for Cimzia certolizumab pegol...
...it is working with FDA and a third party bioanalytical laboratory to address the issue. Cimzia...
...against tumor necrosis factor (TNF) alpha . Under a 2014 deal, Dermira Inc. (NASDAQ:DERM) shares Cimzia's...
Items per page:
1 - 10 of 335